Live Breaking News & Updates on Muscular Dystrophy Patient

Stay updated with breaking news from Muscular dystrophy patient. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

– Announced positive 12-month topline results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy –

– Advancing Phase 2 trial of EDG-5506 in Becker muscular.
-Today at 08:03 am- MarketScreener ....

United States , Duchenne Becker , Kevin Koch , Drug Administration , Research Row , Edgewise Therapeutics Inc , Securities Exchange , Exchange Commission , Edgewise Therapeutics , Chief Executive Officer , Month Topline Results , Label Study , First In Class Sarcomere Modulator , Muscular Dystrophy Patient , Parent Project Muscular Dystrophy , Annual Conference , Fast Track , Limb Girdle , Functional Changes , Becker Muscular Dystrophy , Clinical Trials , Scientific Reports , Selection Approach , Optimal Biomarker Using Quantitative Muscle , Functional Assessments , Securities Act ,